Allogene Therapeutics, Inc.
ALLO
$2.13
$0.073.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 28.67% | 35.25% | 37.55% | 23.23% | 8.10% |
| Total Depreciation and Amortization | -7.42% | -5.44% | -3.43% | -14.76% | -12.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.54% | -43.30% | -64.97% | -36.94% | 7.17% |
| Change in Net Operating Assets | 321.50% | -103.83% | 97.60% | 87.84% | -46.80% |
| Cash from Operations | 75.60% | 24.79% | 32.70% | 38.62% | 5.31% |
| Capital Expenditure | 90.91% | 100.00% | 43.36% | -- | -1,137.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -571.38% | -39.10% | 116.12% | -41.19% | -71.66% |
| Cash from Investing | -579.08% | -38.81% | 115.71% | -41.25% | -72.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 98.52% | 36.84% | 376.58% | -98.58% | 544.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 56.05% | -- |
| Cash from Financing | 50.98% | 36.84% | 376.58% | -95.33% | 747.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.75% | -42.15% | 87.84% | -91.74% | -2.01% |